Silence Therapeutics plc

At $19.75, Silence Therapeutics' price is 236376% above the $0.01 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

Intrinsiqq's calculator puts Silence Therapeutics' fair value at $0.01 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 3.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.01. Every input can be changed on the Intrinsic Value tab.

Silence Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$72M, and its weakest is return on capital at -96.0%. The Quality tab shows every check against its target.

No. Silence Therapeutics (SLN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.